An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab
Who is this study for? Patients with Psoriasis
What treatments are being studied? Enstilar 0.005%-0.064% Topical Foam
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male or female adult ≥ 18 years of age;
• Diagnosis of chronic plaque-type
• Patient with 2-10% BSA
• Physician Global Assessment of 2 or greater
• Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
Locations
United States
New Jersey
Psoriasis Treatment Center of Central New Jersey
RECRUITING
East Windsor
Contact Information
Primary
Jerry Bagel, MD
dreamacres1@aol.com
6094434500
Backup
Elise Nelson
enelson@windsordermatology.com
6094434500
Time Frame
Start Date: 2019-01-16
Estimated Completion Date: 2019-12-15
Participants
Target number of participants: 30
Treatments
Experimental: Open Label Enstilar
once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Related Therapeutic Areas
Sponsors
Collaborators: LEO Pharma
Leads: Psoriasis Treatment Center of Central New Jersey